Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Cancer Res (2022) 82 (12_Supplement): CT160.

DOI: https://doi.org/10.1158/1538-7445.AM2022-CT160

Published: 15 June 2022

View article

Journal Articles

Abstract 594: FcγRIIB expressed on activated CD8⁺ T cells restrains T cell responsiveness to αPD-1 immune checkpoint blockade in melanoma patients

Kelsey B. Bennion, Marvi Tariq, Kirsten M. Baecher, Chrystal M. Paulos, Ragini Kudchadkar, Michael C. Lowe, Mandy L. Ford

Cancer Res (2022) 82 (12_Supplement): 594.

DOI: https://doi.org/10.1158/1538-7445.AM2022-594

Published: 15 June 2022

View article

Journal Articles

Abstract 247: Identification of the GABA_A receptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives

Cancer Res (2019) 79 (13_Supplement): 247.

DOI: https://doi.org/10.1158/1538-7445.AM2019-247

Published: 01 July 2019

View article

Journal Articles

Abstract 2607: Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)

Cancer Res (2018) 78 (13_Supplement): 2607.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2607

Published: 01 July 2018

View article

Journal Articles

Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Cancer Res (2016) 76 (14_Supplement): CT096.

DOI: https://doi.org/10.1158/1538-7445.AM2016-CT096

Published: 15 July 2016

View article

Journal Articles

Abstract 809: BRAF wild-type melanoma survival hinges upon AKT activity and adaptive autophagic reprogramming in response to chemotherapy

Vito W. Rebecca, Renato Massaro, Inna Fedorenko, Geoffrey T. Gibney, Vernon K. Sondak, Ravi K. Amaravadi, Shengkan Jin, Silvya S. Maria-Engler, Ragini Kudchadkar, Keiran S. M. Smalley

Cancer Res (2014) 74 (19_Supplement): 809.

DOI: https://doi.org/10.1158/1538-7445.AM2014-809

Published: 01 October 2014

View article

Journal Articles

Abstract 1659: Exhaustion of autophagy-mediated cell survival underlies the pre-clinical and clinical activity of chemotherapy combined with the AKT inhibitor MK-2206 in BRAF wild-type melanoma.

Vito W. Rebecca, Renato R. Massaro, Silvya S. Maria-Engler, Jane L. Messina, Geoffrey T. Gibney, Vernon K. Sondak, Ragini Kudchadkar, Keiran S. Smalley

Cancer Res (2013) 73 (8_Supplement): 1659.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1659

Published: 15 April 2013

View article

NARROW

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Abstract 594: FcγRIIB expressed on activated CD8⁺ T cells restrains T cell responsiveness to αPD-1 immune checkpoint blockade in melanoma patients

Abstract 247: Identification of the GABA_A receptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives

Abstract 2607: Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)

Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Abstract 809: BRAF wild-type melanoma survival hinges upon AKT activity and adaptive autophagic reprogramming in response to chemotherapy

Abstract 1659: Exhaustion of autophagy-mediated cell survival underlies the pre-clinical and clinical activity of chemotherapy combined with the AKT inhibitor MK-2206 in BRAF wild-type melanoma.

Email alerts

AACR Journals

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Abstract 594: FcγRIIB expressed on activated CD8+ T cells restrains T cell responsiveness to αPD-1 immune checkpoint blockade in melanoma patients

Abstract 247: Identification of the GABAA receptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives

Abstract 2607: Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)

Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Abstract 809: BRAF wild-type melanoma survival hinges upon AKT activity and adaptive autophagic reprogramming in response to chemotherapy

Abstract 1659: Exhaustion of autophagy-mediated cell survival underlies the pre-clinical and clinical activity of chemotherapy combined with the AKT inhibitor MK-2206 in BRAF wild-type melanoma.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract 594: FcγRIIB expressed on activated CD8⁺ T cells restrains T cell responsiveness to αPD-1 immune checkpoint blockade in melanoma patients

Abstract 247: Identification of the GABA_A receptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives